-
Je něco špatně v tomto záznamu ?
Inotropika u pacientů s onemocněním srdce - aktuální stav v roce 2011
[Inotropes in cardiac patients: Update 2011]
John T. Parissis, Pinelopi Rafouli-Stergiou, Vassilios Stasinos, Panagiotis Psarogiannakopoulos, Alexandre Mebazaa
Jazyk čeština Země Česko
Typ dokumentu přehledy
- MeSH
- kardiotonika terapeutické užití MeSH
- kritický stav terapie MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
ICU patients frequently develop low output syndromes due to cardiac dysfunction, myocardial injury, and inflammatory activation. Conventional inotropic agents seem to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of ICU patients, having no serious adverse effects. This review summarizes all the current knowledge about the use of conventional and new inotropic agents in various clinical entities of critically ill patients. RECENT FINDINGS: In recent European Society of Cardiology guidelines, inotropic agents are administered in patients with low output syndrome due to impaired cardiac contractility, and signs and symptoms of congestion. The most recommended inotropes in this condition are levosimendan and dobutamine (both class of recommendation: IIa, level of evidence: B). Recent data indicate that levosimendan may be useful in postmyocardial infarction cardiac dysfunction and septic shock through increasing coronary flow and attenuating inflammatory activation, respectively. Furthermore, calcium sensitizing by levosimendan can be effectively used for weaning of mechanical ventilation in postcardiac surgery patients and has also cardioprotective effect as expressed by the absence of troponin release in this patient population. Finally, new agents, such as istaroxime and cardiac myosin activators may be safe and improve central hemodynamics in experimental models of heart failure and heart failure patients in phase II clinical trials; however, large-scale randomized clinical trials are required. SUMMARY: In an acute cardiac care setting, short-term use of inotropic agents is crucial for the restoration of arterial blood pressure and peripheral tissue perfusion, as well as weaning of cardiosurgery. New promising agents should be tested in randomized clinical trials.
Inotropes in cardiac patients: Update 2011
Lit.: 84
- 000
- 00000naa 2200000 a 4500
- 001
- bmc11011661
- 003
- CZ-PrNML
- 005
- 20111210211049.0
- 008
- 110525s2011 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Parissis, John T.
- 245 10
- $a Inotropika u pacientů s onemocněním srdce - aktuální stav v roce 2011 / $c John T. Parissis, Pinelopi Rafouli-Stergiou, Vassilios Stasinos, Panagiotis Psarogiannakopoulos, Alexandre Mebazaa
- 246 11
- $a Inotropes in cardiac patients: Update 2011
- 314 __
- $a Heart Failure Unit, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com
- 504 __
- $a Lit.: 84
- 520 9_
- $a ICU patients frequently develop low output syndromes due to cardiac dysfunction, myocardial injury, and inflammatory activation. Conventional inotropic agents seem to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of ICU patients, having no serious adverse effects. This review summarizes all the current knowledge about the use of conventional and new inotropic agents in various clinical entities of critically ill patients. RECENT FINDINGS: In recent European Society of Cardiology guidelines, inotropic agents are administered in patients with low output syndrome due to impaired cardiac contractility, and signs and symptoms of congestion. The most recommended inotropes in this condition are levosimendan and dobutamine (both class of recommendation: IIa, level of evidence: B). Recent data indicate that levosimendan may be useful in postmyocardial infarction cardiac dysfunction and septic shock through increasing coronary flow and attenuating inflammatory activation, respectively. Furthermore, calcium sensitizing by levosimendan can be effectively used for weaning of mechanical ventilation in postcardiac surgery patients and has also cardioprotective effect as expressed by the absence of troponin release in this patient population. Finally, new agents, such as istaroxime and cardiac myosin activators may be safe and improve central hemodynamics in experimental models of heart failure and heart failure patients in phase II clinical trials; however, large-scale randomized clinical trials are required. SUMMARY: In an acute cardiac care setting, short-term use of inotropic agents is crucial for the restoration of arterial blood pressure and peripheral tissue perfusion, as well as weaning of cardiosurgery. New promising agents should be tested in randomized clinical trials.
- 650 _2
- $a kardiotonika $x terapeutické užití $7 D002316
- 650 _2
- $a kritický stav $x terapie $7 D016638
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Rafouli-Stergiou, Pinelopi
- 700 1_
- $a Stasinos, Vassilios
- 700 1_
- $a Psarogiannakopoulos, Panagiotis
- 700 1_
- $a Mebazaa, Alexandre
- 773 0_
- $w MED00156011 $t Current opinion in critical care $g Roč. 5, č. 1 (2011), s. 15-24 $x 1802-3819
- 910 __
- $a ABA008 $b B 2484 $c 422 $y 1
- 990 __
- $a 20110525093044 $b ABA008
- 991 __
- $a 20110525102612 $b ABA008
- 999 __
- $a ok $b bmc $g 852785 $s 717744
- BAS __
- $a 3
- BMC __
- $a 2011 $b 5 $c 1 $d 15-24 $m Current Opinion in Critical Care (České vyd.) $x MED00156011
- LZP __
- $a 2011-08/mkme